Diabetic Nephropathy (DN) also called as diabetic kidney disease (DKD) is a long-term kidney damage or disease that can affect people with diabetes. Diabetic Nephropathy affects the ability of kidney to remove wastes and extra fluid from the body.

The most common cause of Diabetic Nephropathy is Type 1 and Type 2 Diabetes which increase the blood pressure. Any damage caused to blood vessels results in high blood pressure which will increase the pressure in the filtering system of the kidneys, which can cause severe damage lead to decreased kidney function and eventually kidney failure.

Symptoms include swollen ankles, feet, lower legs, or hands due to water retention, frequent urination, high blood pressure, darker urine due to traces of blood, shortness of breath, fatigue due to lack of oxygen in the blood, nausea, vomiting, poor appetite, metallic taste in the mouth, abnormal heart rhythm due to high potassium in blood.

Doctors most often diagnose Diabetic Nephropathy by blood and urine tests, imaging tests, Renal function tests, Kidney biopsy.

The most common treatments for Diabetic Nephropathy are medications which will control the blood pressure, blood sugar, cholesterol level, and protein in the urine for the early stage and dialysis or Kidney transplant for advanced stage.

Report Highlights

Global Insight Service’s, Diabetic Nephropathy – Drug Pipeline Landscape, 2022 report provides an overview of the Diabetic Nephropathy pipeline drugs. This report covers detailed insights on Diabetic Nephropathy drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Diabetic Nephropathy pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.

Methodology

The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.

Scope

The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
    Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
    Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
    Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
    Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.
Table of Contents

List of Tables
List of Figures

1. Introduction
1.1 Diabetic Nephropathy – Pipeline Drugs, 2022-Coverage

2. Disease Overview – Diabetic Nephropathy
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management

3. Diabetic Nephropathy – Pipeline Drugs Development – Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2022
3.3 Products under Development by Companies, 2022

4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.3 Assessment by Route of Administration

5. Drug Profiles
5.1 Clinical Stage Drugs – Phase III
5.1.1. Atrasentan
5.1.2. Bardoxolone Methyl
5.1.3. CS-3150
5.2 Clinical Stage Drugs – Phase II
5.2.1 APX-115
5.2.2 BI 685509
5.2.3 BI 690517
5.2.4 Cotadutide
5.2.5 CSL346
5.2.6 CU01
5.2.7 DM-199
5.2.8 FT011
5.2.9 GFB-024
5.2.10 GFB-887
5.2.11 GLY-230
5.2.12 MPC-300-IV
5.2.13 Nidufexor
5.2.14 Orbcel-M
5.2.15 PH3
5.2.16 Propagermanium
5.2.17 Renal Autologous Cell Therapy
5.2.18 SCO-272
5.2.19 SCO-792
5.2.20 SER150
5.2.21 Tofogliflozin
5.2.22 Tozorakimab
5.3 Clinical Stage Drugs – Phase I
5.3.1 CLBS201
5.3.2 FM101
5.3.3 HEC73077
5.3.4 INV-202
5.3.5 Nimacimab
5.3.6 OCX063
5.4 Early Stage Drugs – IND/CTA Filed
5.4.1 Dorzagliatin
5.5 Early Stage Drugs – Preclinical
5.5.1 A717
5.5.2 AP303
5.5.3 BLR-200
5.5.4 FB216A1-1
5.5.5 GMA131
5.5.6 LABP-69
5.5.7 O304
5.5.8 SCO-116
5.5.9 SER-130
5.5.10 SER-140
5.5.11 VAR 200-03
5.6 Early Stage Drugs – Discovery
5.6.1 ARP-1536
5.6.2 IC 100
5.6.3 Razuprotafib

6. Key Regulatory Designations

7. Key Deals

8. Key Upcoming Milestones

9. Key Companies Involved
9.1 Aadi Biosciences
9.2 Alebund Pharmaceuticals
9.3 AptaBio Therapeutics Inc
9.4 AstraZeneca
9.5 Betagenon AB
9.6 Bird Rock Bio Inc
9.7 BLR Bio LLC
9.8 Boehringer Ingelheim
9.9 Caladrius Biosciences Inc
9.10 CSL Behring
9.11 Certa Therapeutics Pty Ltd
9.12 Chinook Therapeutics
9.13 Curacle Co Ltd
9.14 Daiichi Sankyo Co Ltd
9.15 DiaMedica Therapeutics Inc
9.16 Dimerix Bioscience Pty Ltd
9.17 Frontbio Co Ltd
9.18 Future Medicine Co Ltd
9.19 Glycadia Inc
9.20 Gmax Biopharm LLC
9.21 Goldfinch Bio Inc
9.22 Hua Medicine Shanghai Ltd
9.23 Inversago Pharma Inc
9.24 Kowa Company Ltd
9.25 Kyowa Kirin Co Ltd
9.26 Landos Biopharma Inc
9.27 Mesoblast Ltd
9.28 Novartis Pharmaceuticals
9.29 Occurx
9.30 Orbsen Therapeutics Ltd
9.31 PhytoHealth Corporation
9.32 Prokidney
9.33 Scohia Pharma Inc
9.34 Serodus ASA
9.35 Sunshine Lake Pharma Co Ltd
9.36 ZyVersa Therapeutics Inc

10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs

11. Appendix

List of Tables

Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2.1 Clinical Trial Details – Atrasentan/Chinook Therapeutics
Table 2.2 Clinical Trial Details – Bardoxolone Methyl/Kyowa Kirin Co Ltd
Table 2.3 Clinical Trial Details – CS-3150/Daiichi Sankyo Co Ltd
Table 2.4 Clinical Trial Details – APX-115/AptaBio Therapeutics Inc
Table 2.5 Clinical Trial Details – BI 685509/Boehringer Ingelheim
Table 2.6 Clinical Trial Details – BI 690517/Boehringer Ingelheim
Table 2.7 Clinical Trial Details – Cotadutide /AstraZeneca
Table 2.8 Clinical Trial Details – CSL346/CSL Behring
Table 2.9 Clinical Trial Details – CU01/Curacle Co Ltd
Table 2.10 Clinical Trial Details – DM-199/DiaMedica Therapeutics Inc
Table 2.11 Clinical Trial Details – FT011/Certa Therapeutics Pty Ltd
Table 2.12 Clinical Trial Details – GFB-024/Goldfinch Bio Inc
Table 2.13 Clinical Trial Details – GFB-887/Goldfinch Bio Inc
Table 2.14 Clinical Trial Details – GLY-230/Glycadia Inc
Table 2.15 Clinical Trial Details – MPC-300-IV/Mesoblast Ltd
Table 2.16 Clinical Trial Details – Nidufexor/Novartis Pharmaceuticals
Table 2.17 Clinical Trial Details – Orbcel-M/Orbsen Therapeutics Ltd
Table 2.18 Clinical Trial Details – PH3/PhytoHealth Corporation
Table 2.19 Clinical Tral Details – Propagermanium/Dimerix Bioscience Pty Ltd
Table 2.20 Clinical Trial Details – Renal Autologous Cell Therapy/Prokidney
Table 2.21 Clinical Trial Details – SCO-272/Scohia Pharma Inc
Table 2.22 Clinical Trial Details – SCO-792/Scohia Pharma Inc
Table 2.23 Clinical Trial Details – SER150/Serodus ASA
Table 2.24 Clinical Trial Details – Tofogliflozin /Kowa Company Ltd
Table 2.25 Clinical Trial Details – Tozorakimab/AstraZeneca
Table 2.26 Clinical Trial Details – CLBS201/Caladrius Biosciences Inc
Table 2.27 Clinical Trial Details – FM101/Future Medicine Co Ltd
Table 2.28 Clinical Trial Details – HEC73077 /Sunshine Lake Pharma Co Ltd
Table 2.29 Clinical Trial Details – INV-202/Inversago Pharma Inc
Table 2.30 Clinical Trial Details – Nimacimab/Bird Rock Bio Inc
Table 2.31 Clinical Trial Details – OCX063 /Occurx
Table 2.32 Clinical Trial Details – Dorzagliatin /Hua Medicine Shanghai Ltd
Table 2.33 Clinical Trial Details – A717/Glycadia Inc
Table 2.34 Clinical Trial Details – AP303/Alebund Pharmaceuticals
Table 2.35 Clinical Trial Details – BLR-200/BLR Bio LLC
Table 2.36 Clinical Trial Details – FB216A1-1/Frontbio Co Ltd
Table 2.37 Clinical Trial Details – GMA131/Gmax Biopharm LLC
Table 2.38 Clinical Trial Details – LABP-69/Landos Biopharma Inc
Table 2.39 Clinical Trial Details – O304/Betagenon AB
Table 2.40 Clinical Trial Details – SCO-116/Scohia Pharma Inc
Table 2.41 Clinical Trial Details – SER-130/Serodus ASA
Table 2.42 Clinical Trial Details – SER-140/Serodus ASA
Table 2.43 Clinical Trial Details – VAR 200-03/ZyVersa Therapeutics Inc
Table 2.44 Clinical Trial Details – ARP-1536/Aadi Biosciences
Table 2.45 Clinical Trial Details – IC 100/ZyVersa Therapeutics Inc
Table 2.46 Clinical Trial Details – Razuprotafib/Aadi Biosciences
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4. 1 Discontinued Drugs

List of Figures

Figure 1. 1 Number of Products under Development for Diabetic Nephropathy , 2022
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Diabetic Nephropathy , 2022
Figure 1. 3 Products by Top 5 Mechanism of Action for Diabetic Nephropathy , 2022
Figure 1. 4 Products by Top 5 Molecule Type for Diabetic Nephropathy , 2022
Figure 1. 5 Products by Top 5 Route of Administration for Diabetic Nephropathy , 2022

Report Segmentation
  • Assessment by Stage of Development
  • Assessment by Companies
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Molecule Type
  • Assessment by Route of Administration

Order this Report

Have questions about the scope of the report ?

Have specific requirements ?

Budget Constraints ?

Related Reports

Premature ejaculation is a type of sexual dysfunction…
Irritable bowel syndrome (IBS) is a group of…
The H1N1 flu (swine flu) is primarily caused…